Home/Filings/4/0000950170-25-046271
4//SEC Filing

Graham G. Walmsley 4

Accession 0000950170-25-046271

CIK 0001744659other

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 7:42 PM ET

Size

8.9 KB

Accession

0000950170-25-046271

Insider Transaction Report

Form 4
Period: 2025-03-25
Transactions
  • Purchase

    Common Stock

    2025-03-27$43.55/sh+50,000$2,177,7001,200,000 total(indirect: See Footnote 1)
  • Purchase

    Common Stock

    2025-03-25$44.75/sh+91,309$4,085,8041,091,309 total(indirect: See Footnote 1)
  • Purchase

    Common Stock

    2025-03-26$43.01/sh+58,691$2,524,4171,150,000 total(indirect: See Footnote 1)
Holdings
  • Common Stock

    2,168
Footnotes (1)
  • [F1]The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Documents

1 file

Issuer

Akero Therapeutics, Inc.

CIK 0001744659

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001777517

Filing Metadata

Form type
4
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 7:42 PM ET
Size
8.9 KB